PET Tumor Board: GRU Trilogy

E. David Crawford, MD; Phillip J. Koo, MD; Paul L. Nguyen, MD; and Daniel P. Petrylak, MD, presented “PET Tumor Board: GRU Trilogy” for the Grand Rounds in Urology audience in November 2023.

How to cite: Crawford, E. David. MD, Koo, Phillip J., MD, Nguyen, Paul L., MD, and Petrylak, Daniel P., MD. “PET Tumor Board: GRU Trilogy.” November 2023. Accessed Apr 2024. https://grandroundsinurology.com/pet-tumor-board-2/

PET Tumor Board: GRU Trilogy – Summary

In this discussion, the second in a trilogy on PSMA PET supported by Blue Earth Diagnostics, three experts join E. David Crawford, MD, Editor-in-Chief at Grand Rounds in Urology, to discuss a challenging case study. Dr. Crawford introduces the case study of a 68-year-old male with rising prostate-specific antigen (PSA) levels one year after a radical prostatectomy to a panel of experts comprised of:

Phillip J. Koo, MD – Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center.
Paul L. Nguyen, MD – Director for Radiation Oncology at the Dana-Farber/ Bringham and Women’s Genitourinary Clinical Center; Vice-Chair of Clinical Research in the Department of Radiation Oncology and Professor at Harvard Medical School; Baldwin-Politi Distinguished Chair in Oncology and Associate Director of the Harvard Radiation Oncology Residency Program at Brigham and Women’s Hospital in Boston, Massachusetts.
Daniel P. Petrylak, MD – Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut.

After reviewing the background of the case, Dr. Crawford displays the patient’s scans. The board analyzes the results of the scans and calls attention to nodes near the patient’s iliac bone and prostate bed which could indicate recurrence.

As the results of multiple tests on the patient are revealed, Dr. Petrylak, Dr. Nguyen, and Dr. Koo offer their insights into appropriate treatments for the patient. These range from treating the patient with SBRT to focal radiation therapy and ADT. When the patient’s final tests are revealed, the board decides on a course of finasteride and a 3-month follow-up.

This is the second talk in a trilogy of discussions on PSMA PET supported by Blue Earth Diagnostics. For the first installment, click here.